Moderna Stock Falls After Cancer Vaccine Data Leaks
Moderna shares fell after test results for its new cancer shot leaked to the public.
Moderna stock took a hit today. Investors sold off shares after test data for a new cancer shot leaked online early. The drug comes from a team effort with drug maker Merck.
The numbers show good news for cancer patients. The treatment helps fight severe skin cancer alongside Merck's top drug. Still, the market wanted even stronger numbers. Traders expected higher survival rates before the formal medical meeting.
Moderna published its full report quickly to calm Wall Street. The medicine trains the immune system to hunt down tumor cells. The surprise leak broke the normal release plan, which triggered confusion on the trading floor.
Medical progress rarely moves in a straight line. Short-term market drops happen when high hopes meet complex medical data. Strong treatments often prove their value over time.
Source: CNBC
More from Biotech
